Furthermore, the increasing focus on precision medicine and biologics, such as monoclonal antibodies and gene therapies, showcases a shift toward innovative treatment modalities. These APIs are often more complex than traditional small molecules, presenting challenges in manufacturing and regulatory approval processes.